An observational study in Chronic Obstructive Lung Disease and Airflow Obstruction, sponsored by Centre Hospitalier de la côte Basque. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Centre Hospitalier de la côte Basque · Observational
Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.
Chronic Obstructive Pulmonary Disease (COPD), a chronic bronchial disease characterized by irreversible airway obstruction, represents a major public health issue. It is currently the fifth leading cause of death worldwide and, according to the World Health Organization (WHO), is expected to become the third leading cause by 2030. Diagnosis is currently based on spirometry, which reveals an obstructive ventilatory disorder (OVD) defined by a forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of less than 0.7. However, limited access to this examination can make the diagnosis of COPD difficult. Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. A French study involving 424 patients hospitalized for a COPD exacerbation found that 21.9% had not been diagnosed previously, meaning they entered the disease during a severe exacerbation. The main challenge, therefore, lies in the early identification of COPD patients, particularly through the use of validated self-questionnaires (e.g., Haute Autorité de Santé). We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population. The secondary objectives are: to compare the clinical characteristics of patients with and without AO / with and without PRISm (depending on sample size). To identify risk factors for AO and/or PRISm (depending on sample size) (female sex, advanced age, BMI, active smoking, respiratory symptoms). To estimate the prevalence of "undiagnosed" subjects, defined as the presence of OVD without any known respiratory history, and to study their clinical characteristics. We plan to follow up with participants at 6 months through a telephone contact to assess the practical impact of this screening day and to determine the proportion of those who have received a consultation with a general practitioner, a pulmonologist, or the introduction of a treatment.
4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.
This study's planned enrollment of 200 is above the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Centre Hospitalier de la côte Basque is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Population attending the "9 Mai Poumon 2026" prevention campaign
Spirometry to identify airflow obstruction and PRISm (Preserved ration impaired spirometry)
Prevalence of newly diagnosed airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population
Percentage of AO and PRISm detected
Time frame: On the day of inclusion
Description of the clinical characteristics of patients with and without Airflow Obstruction / with and without PRISm
Percentage of presence of symptoms, specific treatment
Time frame: At the day of inclusion
Description of the population participating to the prevention campaing
Percentage of presence of tabagism
Time frame: At the day of inclusion
Evaluation of the number of patients diagnosed with airflow obstruction or Prism and who attend a consult with a medical doctor after the prevention campain
Percentage of patients with a medical follow-up at 6 months
Time frame: At Month 6
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→
Centre Hospitalier de la côte Basque